The Latest
- Mar 25, 2020Beacon Securities Research Report On Medx Health Corp.
- Mar 17, 2020Medx Receives Regulatory Approval In Brazil
- Jan 30, 2020Medx Health Corp. Announces Non-brokered Private Placement
- Jan 16, 2020Medx Health Corp. Announces Granting Of Stock Options
- Jan 16, 2020Medx Receives Major Siascope Order For Launch Of Its Dermsecure Platform In Brazil
Reports and Filings
- May 23, 2017Interim Financial Statements/Report - English
- May 01, 2017Audited Annual Financial Statements - English
- May 01, 2017MD&A - English
- Nov 28, 2016MD&A - English
- Nov 28, 2016Interim Financial Statements/Report - English
- Aug 26, 2016Interim Financial Statements/Report - English
- May 30, 2016MD&A - English
- May 30, 2016Interim Financial Statements/Report - English
- Apr 29, 2016Audited Annual Financial Statements - English
- Apr 29, 2016MD&A - English
MedX is committed to technology that is safe and effective.
The safety and effectiveness for patients is our first priority. SIAcopy is rapid, patient friendly, accurate, easy to use, and practice friendly. SIAscopy has been used for over 12 years and is supported by over 15 published clinical studies and 24 in vivo clinical posters. MedX Health designs, develops and distributes innovative imaging and software technologies that has been tested for safety and effectiveness and has been cleared and licensed for use in Canada, European Union, and Australia.
The technology has gone through stringent testing and it has been cleared for sale by the following regulatory bodies: Health Canada, CE and ARTG.